Jeff Davis of Acer Therapeutics joined us for World Orphan Drug Congress USA 2015 to present about ‘Developing Therapeutics for the Treatment of (Ultra) Orphan Diseases With Significant Unmet Medical Needs’.
Download the presentation now to learn about:
- Normal Branched-chain Amino Acid Metabolism
- NaPBA: Scientific Rationale for Lowering Leucine
- NaPBA: Clinical Proof-of-Concept Study in MSUD
- ACER-001: Pivotal Study Design/Development Plan
…and much more!
Get your copy here!
To find out more about how Acer Therapeutics is developing therapeutics for treatment of (ultra) orphan diseases , join us at World Orphan Drug Congress USA 2016 April 20-22 in Washington, DC.